Loading...
NPI 1598820235 · Brooklyn, NY · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Sherman Abrams Laboratory Inc is a clinical medical laboratory provider located in Brooklyn, New York. This profile covers 265 Medicare and 388 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Sherman Abrams Laboratory Inc |
| Address | 63 Flushing Ave Unit 292 |
| City | Brooklyn |
| State | NY |
| ZIP | 11205 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 22, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $107.9M |
| Medicare | $8M |
This provider is effectively Medicaid‑dominant: total Medicare revenue is $8M versus total Medicaid revenue of $107.9M, so Medicaid represents the vast majority of billed dollars in the dataset. Analysts should treat this entity as primarily a Medicaid-facing laboratory when evaluating network exposure and contracting leverage.
Medicare revenue is moderately concentrated: the top three Medicare codes (87636, 87637, 82306) account for 27.9% of this provider's total Medicare revenue. Those top codes combine high-volume respiratory multiplex testing (87636, 87637) with routine clinical chemistry (82306 Vitamin D), indicating a mixed portfolio of infectious-disease panels and standard lab panels driving more than a quarter of Medicare receipts.
Medicaid revenue is highly concentrated: the top three Medicaid codes (U0004, 0202U, 87798) account for 47.3% of this provider's total Medicaid revenue. The three codes are large-scale SARS‑CoV‑2/COVID and multiplex infectious-agent tests (U0004 $18.1M with 292.6K claims, 0202U $11.5M with 43.3K claims, and 87798 $9.4M with 140.9K claims), showing that pandemic-era and multiplex respiratory testing dominate Medicaid dollars.
The overall code mix points to a high-volume reference laboratory that combines mass infectious/respiratory testing with common outpatient clinical assays: high counts for U0004, 87637, 87798, and 87801 on Medicaid sit alongside routine tests such as 82306, 84443, 80061, and 80053. This blend suggests operations capable of both high-throughput molecular diagnostics and standard chemistry/immunoassay workflows, which has implications for capacity, instrument footprint, and payer contract design.
National competitive standing on Medicare is unusually strong for multiple codes: several Medicare codes rank at the 100th percentile or near it (for example 87636 ranks #11 of 2192 providers, 82306 ranks #53 of 12453 providers), and select codes are labeled as extreme outliers (e.g., 87581 ranks #3 of 303 providers nationally, described as an "extreme outlier, far above typical national volume for this code"). These national percentile positions indicate that the provider processes materially higher Medicare volumes than typical peers for those tests.
Statewide competitive standing on Medicaid is dominant for core testing lines: U0004 ranks #1 of 98 providers in-state (100th percentile; extreme outlier), 0202U ranks #1 of 48 providers in-state (100th percentile; extreme outlier), and multiple other codes (87637, 87798, 87801, 87486, 87581) also rank #1 in-state. The provider’s claim volumes such as 292.6K claims for U0004 and 225.4K claims for 87801 demonstrate a scale that places it among the largest Medicaid lab suppliers in New York for respiratory and multiplex testing.
Several individual codes are flagged as statistical outliers and merit operational and payer review: Medicare codes such as 82747 (ranks #1 of 128 providers nationally; "extreme outlier") and 87581 ("extreme outlier") and many Medicaid codes that are "extreme outlier, far above typical state volume for this code" indicate highly concentrated test lines. Payors and network managers should interpret these labels as a signal of outsized volume in specific tests (not as an inference of intent) and consider audit, utilization management, or contracting strategies focused on the named codes.
The provider has an established presence with an NPI enumeration date of 2006-12-22 (~20 years ago), which, combined with the large Medicaid footprint and high-volume testing lines, is consistent with a long-running reference-lab operation rather than a recent or transient testing entity. Tenure plus the observed service mix supports treating this entity as an experienced, high-throughput laboratory partner in payer planning and capacity assessments.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
265 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 4,330 | $140 | $606.5K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 4,080 | $140 | $571.1K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 17,710 | $30 | $513.6K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 25,930 | $20 | $414.8K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 29,200 | $10 | $379.6K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 36,040 | $10 | $360.4K |
| 87634 | The lab analyst performs a test for respiratory syncytial virus (RSV) antigen detection using amplified nucleic acid probe technique. | 4,310 | $70 | $297.2K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 8,650 | $30 | $294.2K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 8,640 | $30 | $293.7K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 36,620 | $10 | $292.9K |
Showing 1–10 of 265
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 265 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
265 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| P9604 | 9 | 10 | 1,880 | $20 | $306.6K |
| 87798 | 7 | 40 | 740 | $30 | $218.3K |
| U0004 | 3 | 20 | 450 | $70 | $114.7K |
| 87507 | 1 | 10 | 120 | $410 | $83.7K |
| G0480 | 12 | 30 | 170 | $110 | $76.5K |
| 87801 | 3 | 20 | 60 | $70 | $75.1K |
| 87581 | 1 | 10 | 350 | $30 | $64.6K |
| 87486 | 1 | 10 | 350 | $30 | $64.2K |
| G0482 | 13 | 30 | 90 | $190 | $61.8K |
| 88305 | 249 | 980 | 370 | $50 | $58.5K |
Showing 1–10 of 265
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
388 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 292,610 | $60 | $18.1M |
| 0202U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0202U for the… | 43,310 | $270 | $11.5M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 140,950 | $70 | $9.4M |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 145,540 | $60 | $8.4M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 225,440 | $20 | $5M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 227,120 | $20 | $4.5M |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 200,380 | $20 | $3.2M |
| 86769 | The lab analyst performs a multiple–step immunoassay to evaluate the patient’s serum for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), which causes coronavirus disease… | 109,140 | $30 | $2.9M |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 193,040 | $10 | $2.3M |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 192,850 | $10 | $2.3M |
Showing 1–10 of 388
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
388 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 1 | 100 | 1,490 | $70 | $1.3M |
| 81408 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 9 molecular pathology code. | 2 | 10 | 610 | $1,180 | $831.4K |
| 81412 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least nine genes that the code descriptor lists, relating to disorders… | 2 | 10 | 440 | $1,220 | $536.7K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 23 | 140 | 360 | $130 | $492.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 8 | 300 | 1,710 | $20 | $458.6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 41 | 110 | 690 | $50 | $442K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 9 | 290 | 1,900 | $30 | $390.6K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 9 | 30 | 550 | $100 | $359.8K |
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 11 | 60 | 230 | $370 | $340.9K |
| 0202U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0202U for the… | 1 | 50 | 420 | $110 | $334.5K |
Showing 1–10 of 388
Other providers in the same ZIP code as Sherman Abrams Laboratory Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Parcare Community Health Network Inc | NY | Multi-Specialty Clinic/Center | $0 | $88.5M |
| New York City Health And Hospitals Corporation | NY | Clinic/Center | $0 | $48.8M |
| White Aid Medical Supply Inc | NY | Durable Medical Equipment & Medical Supplies | $0 | $48.3M |
| Andras Fenyves | NY | Internal Medicine Physician | $900.1K | $2.4M |
| Preventive Diagnostics Inc | NY | Mobile Radiology Clinic/Center | $574.3K | $429.9K |
| Jean Hayward | NY | Family Nurse Practitioner | $365.4K | $11.9K |
| Shani Shah | NY | Physical Therapist | $198.6K | $6.1K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.